Evidence map›Paper›PMID 38638429›Full record

ArticleFrontiers in immunology2024

Immunoglobulin-like transcript 2 as an impaired anti-tumor cytotoxicity marker of natural killer cells in patients with hepatocellular carcinoma.

Toshihiro Sakata, Sachiyo Yoshio, Taiji Yamazoe, Taizo Mori, Eiji Kakazu, Yoshihiko Aoki, Nobuyoshi Aoyanagi, Toru Okamoto, Takanori Ito, Hidenori Toyoda and 5 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 7 institutions in 1 country.

Toshihiro SakataDepartment of Liver Diseases, The Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, Chiba, Japan.
Sachiyo YoshioDepartment of Liver Diseases, The Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, Chiba, Japan.
Taiji YamazoeDepartment of Liver Diseases, The Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, Chiba, Japan.
Taizo MoriDepartment of Liver Diseases, The Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, Chiba, Japan.
Eiji KakazuDepartment of Liver Diseases, The Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, Chiba, Japan.
Yoshihiko AokiKohnodai Hospital, National Center for Global Health and Medicine, Chiba, Japan.
Nobuyoshi AoyanagiKohnodai Hospital, National Center for Global Health and Medicine, Chiba, Japan.
Toru OkamotoDepartment of Microbiology, Juntendo University School of Medicine, Tokyo, Japan.
Takanori ItoDivision of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Aichi, Japan.
Hidenori ToyodaDepartment of Gastroenterology, Ogaki Municipal Hospital, Gifu, Japan.
Takumi KawaguchiDivision of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Fukuoka, Japan.
Yoshihiro OnoDivision of Hepatobiliary and Pancreatic Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Yu TakahashiDivision of Hepatobiliary and Pancreatic Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Akinobu TaketomiDepartment of Gastoenterological Surgery I, Hokkaido University Graduate School of Medicine, Hokkaido, Japan.
Tatsuya KantoDepartment of Liver Diseases, The Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, Chiba, Japan.
National Center for Global Health and Medicine · JPJapanese Foundation For Cancer Research · JPHokkaido University · JPJuntendo University · JPKurume University · JPNagoya University · JPOgaki Municipal Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Natural killer (NK) cells play a pivotal role in immune surveillance in the liver. We aimed to identify potential targets for NK cell-mediated immune intervention by revealing the functional molecules on NK cells in HCC patients. Methods: To evaluate the impact of aging on NK cell phenotypes, we examined NK cells from healthy volunteers (HVs) of various ages. Because ILT2 expression on CD56 Results: ILT2-positive CD56 Conclusions: In HCC patients, ILT2 is a signature molecule for cancerous CD56

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsBiomarkers, TumorHumansImmunoglobulinsKiller Cells, NaturalBiomarkers, TumorImmunoglobulinsADCCHCCHLA-GILT2MIFNK cells

Identifiers

PMID38638429
PMCPMC11024250
OpenAlexW4393944416

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.